Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide

Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide

Recurrence of glomerulonephritis is the third-leading cause of allograft loss. Graft loss due to IgA nephropathy occurs in 10% at 10-year follow-up. The NEFIGAN trial demonstrated that Target Release Formulation (TRF) of budesonide is a specific treatment for IgA nephropathy targeting intestinal muc...

Full description

Bibliographic Details
Main Authors: Umesh Lingaraj, Kishan Aralapuram, Sreedhara Chikkanayakanhalli, Akila Vishwanathan, Mahesha Vankalakunti
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Saudi Journal of Kidney Diseases and Transplantation
Online Access:http://www.sjkdt.org/article.asp?issn=1319-2442;year=2020;volume=31;issue=2;spage=521;epage=523;aulast=Lingaraj

Internet

http://www.sjkdt.org/article.asp?issn=1319-2442;year=2020;volume=31;issue=2;spage=521;epage=523;aulast=Lingaraj

Similar Items